Previous 10 |
home / stock / akblf / akblf news
ROUND ROCK, Texas , Sept. 28, 2019 /PRNewswire/ -- ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) is pleased to join several organizations as a sponsor of the third annual National Penicillin Allergy Day, an awareness day to help educate the community on penicillin allergies and t...
HØRSHOLM, Denmark , June 3, 2019 /PRNewswire/ -- Zydis ® freeze-dried tablet technology used in ALK's SLIT-tablet range makes them faster dissolving than conventional compressed sublingual tablets in in-vitro testing. Resulting in rapid and predictable release of the ac...
- Easy to measure biomarkers could identify a group of patients who benefit even more from ACARIZAX® treatment of house dust mite (HDM)-induced allergic asthma - Early identification of patients would allow earlier treatment intervention - With its HDM SLIT-tablet, ALK is well-plac...
ALK-Abelló A/S ( OTCPK:AKBLF ): Q1 net income of DKK89M More news on: ALK-Abelló A/S, ALK-Abelló A/S, Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Alk-Abello A/S Company Name:
AKBLF Stock Symbol:
OTCMKTS Market:
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position...
Company release No. 11/2024 ALK delivers 10 % organic revenue growth with operating profit up 41 % in Q1 and upgrades outlook The growth in ALK's overall sales was primarily driven by the European tablet sales, which were boosted by the inflow of new patients and improved ...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the B...